b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Data-Review" Owner="NLM">\n        <PMID Version="1">30946523</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>06</Month>\n            <Day>01</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1464-410X</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>125</Volume>\n                    <Issue>6</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Jun</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>BJU international</Title>\n                <ISOAbbreviation>BJU Int.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>810-816</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1111/bju.14768</ELocationID>\n            <Abstract>\n                <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To report the long-term oncological outcomes of a randomised trial comparing androgen-deprivation therapy (ADT) combined with external beam radiation therapy (EBRT) and ADT alone in patients with locally advanced prostate cancer.</AbstractText>\n                <AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">In this multicentre phase III trial, patients were randomly assigned to ADT alone or ADT+EBRT. Leuprorelin 11.25\xc2\xa0mg was administered for 3\xc2\xa0years. The whole pelvis was treated at a dose of 46\xc2\xa0Gy and the prostate with a boost from 20 to 28\xc2\xa0Gy. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), disease-specific survival (DSS), locoregional PFS (LRPFS), metastasis-free survival (MFS), biochemical PFS (BPFS), and tolerance.</AbstractText>\n                <AbstractText Label="RESULTS" NlmCategory="RESULTS">With a median follow-up of 7.3\xc2\xa0years, 263 patients were included. The 8-year PFS rate was significantly higher in the ADT+EBRT arm than in the ADT arm (48% vs 7%; hazard ratio [HR] 0.27, 95% confidence interval [CI] 0.17-0.39; P\xc2\xa0&lt;\xc2\xa00.001); in patients with a baseline PSA level \xe2\x89\xa550\xc2\xa0ng/mL (HR 0.10, 95% CI 0.05-0.20; P\xc2\xa0&lt;\xc2\xa00.001) and in patients with a baseline PSA level &lt;50\xc2\xa0ng/mL (HR 0.28, 95% CI 0.19-0.40; P\xc2\xa0&lt;\xc2\xa00.001). The risk of death from prostate cancer was significantly reduced in the ADT+EBRT arm (sub-HR [SHR] 0.48, 95% CI 0.25-0.91; P\xc2\xa0=\xc2\xa00.02). The 8-year OS rate was 57% in the ADT arm and 65% in the ADT+EBRT arm (no significant difference). LRPFS was significantly in favour of the ADT+EBRT arm (SHR 0.61, 95% CI 0.42-0.89; P\xc2\xa0=\xc2\xa00.01). MFS was comparable between both arms (P\xc2\xa0=\xc2\xa00.88). Analysis of toxicities revealed acute lower tolerance in the ADT+EBRT arm, with a gradual decrease in intensity from 6\xc2\xa0months after the end of EBRT.</AbstractText>\n                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These long-term results confirm the oncological benefit of combining EBRT with ADT in the treatment of locally advanced prostate cancer.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2019 The Authors BJU International \xc2\xa9 2019 BJU International Published by John Wiley &amp; Sons Ltd.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Sargos</LastName>\n                    <ForeName>Paul</ForeName>\n                    <Initials>P</Initials>\n                    <Identifier Source="ORCID">https://orcid.org/0000-0002-7301-0870</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Institut Bergoni\xc3\xa9, Bordeaux, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Mottet</LastName>\n                    <ForeName>Nicolas</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Urology, University Hospital, Saint-Etienne, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Bellera</LastName>\n                    <ForeName>Carine</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Clinical and Epidemiological Research Unit, Institut Bergoni\xc3\xa9, Bordeaux, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Richaud</LastName>\n                    <ForeName>Pierre</ForeName>\n                    <Initials>P</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Radiation Oncology, Institut Bergoni\xc3\xa9, Bordeaux, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <Agency>Laboratories Takeda</Agency>\n                    <Country/>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>03</Month>\n                <Day>02</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>BJU Int</MedlineTA>\n            <NlmUniqueID>100886721</NlmUniqueID>\n            <ISSNLinking>1464-4096</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">androgen-deprivation therapy</Keyword>\n            <Keyword MajorTopicYN="N">prostate cancer</Keyword>\n            <Keyword MajorTopicYN="N">radiotherapy</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>5</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>5</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>5</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30946523</ArticleId>\n            <ArticleId IdType="doi">10.1111/bju.14768</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Title>References</Title>\n            <Reference>\n                <Citation>Bolla M, de Reijke TM, Van Tienhoven G et\xc2\xa0al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-27</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Bolla M, Gonzalez D, Warde P et\xc2\xa0al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295-300</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Bolla M, Van Tienhoven G, Warde P et\xc2\xa0al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066-73</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hanks GE, Pajak TF, Porter A et\xc2\xa0al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003; 21: 3972-8</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Horwitz EM, Bae K, Hanks GE et\xc2\xa0al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008; 26: 2497-504</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Pilepich MV, Winter K, Lawton CA et\xc2\xa0al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285-90</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Souhami L, Bae K, Pilepich M, Sandler H. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 2009; 27: 2137-43</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Pilepich MV, Winter K, John MJ et\xc2\xa0al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-52</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Mason MD, Parulekar WR, Sydes MR et\xc2\xa0al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 2015; 33: 2143-50</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 2012; 62: 213-9</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Warde P, Mason M, Ding K et\xc2\xa0al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 2011; 378: 2104-11</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Widmark A, Klepp O, Solberg A et\xc2\xa0al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-8</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Roach M 3rd, Hanks G, Thames H Jr et\xc2\xa0al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Monti AF, Ostinelli A, Frigerio M et\xc2\xa0al. An ICRU 50 radiotherapy treatment chart. Radiother Oncol 1995; 35: 145-50</Citation>\n            </Reference>\n            <Reference>\n                <Citation>LENT SOMA scales for all anatomic sites. Int J Radiat Oncol Biol Phys 1995; 31: 1049-91</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Bolla M, Collette L, Blank L et\xc2\xa0al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6</Citation>\n            </Reference>\n            <Reference>\n                <Citation>D\'Amico AV, Whittington R, Malkowicz SB et\xc2\xa0al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Mohler J, Bahnson RR, Boston B et\xc2\xa0al. NCCN clinical practice guidelines in oncology: prostate cancer. J Nat Compr Canc Netw 2010; 8: 162-200</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Asbell SO, Martz KL, Shin KH et\xc2\xa0al. Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOG #77-06, a phase III study for T1BN0M0 (A2) and T2N0M0 (B) prostate carcinoma. Int J Radiat Oncol Biol Phys 1998; 40: 769-82</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lawton CA, DeSilvio M, Roach M 3rd et\xc2\xa0al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007; 69: 646-55</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Pommier P, Chabaud S, Lagrange JL et\xc2\xa0al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 2007; 25: 5366-73</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Roach M 3rd, DeSilvio M, Lawton C et\xc2\xa0al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-11</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Roach M 3rd, DeSilvio M, Valicenti R et\xc2\xa0al. Whole-pelvis, \xe2\x80\x9cmini-pelvis\xe2\x80\x9d, or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006; 66: 647-53</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Harris VA, Staffurth J, Naismith O et\xc2\xa0al. Consensus guidelines and contouring atlas for pelvic node delineation in prostate and pelvic node intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 2015; 92: 874-83</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Sargos P, Guerif S, Latorzeff I et\xc2\xa0al. Definition of lymph node areas for radiotherapy of prostate cancer: a critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU). Cancer Treat Rev 2015; 41: 814-20</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Al-Mamgani A, van Putten WL, Heemsbergen WD et\xc2\xa0al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized\xc2\xa0prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 980-8</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Dearnaley DP, Jovic G, Syndikus I et\xc2\xa0al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 2014; 15: 464-73</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Nguyen QN, Levy LB, Lee AK et\xc2\xa0al. Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation. Cancer 2013; 119: 3265-71</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Zapatero A, Guerrero A, Maldonado X et\xc2\xa0al. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial. Lancet Oncol 2015; 16: 320-7</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Fizazi K, Faivre L, Lesaunier F et\xc2\xa0al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 2015; 16: 787-94</Citation>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'